Varian Medical Systems, Inc. (VAR) recently reported having bagged a new customer for its RapidArc radiotherapy technology. The new customer is Hope International Centro de Radioterapia of Guatemala, an important cancer treatment facility in Latin America.
Doctors at Hope International are presently treating four patients – one with recurring prostate cancer, one with a nasal cavity tumor, one with rectal cancer, and one with recurring glioblastoma multiforme- an aggressive type of brain tumor, using Varian’s RapidArc radiotherapy technology.
These are the first set of patients in Latin America to receive treatment using Varian RapidArc radiotherapy technology. The RapidArc radiotherapy technology from Varian uses a fast form of image-guided radiotherapy that enables clinicians to detect a 2-3 mm displacement of the targeted tumor after having positioned the patient for his first treatment. This ensures that the clinicians are accurately targeting the tumor sparing the surrounding tissues to the maximum possible extent.
It has been tested that RapidArc delivers advanced image-guided intensity modulated radiotherapy (IMRT) up to eight times faster than conventional IMRT. Faster treatments are more precise than the conventional IMRT treatments which are slower.
By virtue of the new customer, Varian has entered the Latin American market. This widens Varian’s customer-base and geographical presence, which in turn helps grow the company’s top-line. Varian is a global leading manufacturer of medical devices and software for treating cancer and other medical conditions. The company uses radiotherapy, radiosurgery, proton therapy, and brachytherapy for treating these diseases. In addition, the company supplies informatics software to different cancer clinics, radiotherapy centers and medical oncology practices.
Read the full analyst report on “VAR”
Zacks Investment Research
